Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
B304138-5mg | 5mg | In stock | $129.90 | |
B304138-25mg | 25mg | In stock | $585.90 | |
B304138-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $848.90 |
Potent isozyme selective Akt1/2 kinase inhibitor
Synonyms | Akt inhibitor VIII|612847-09-3|Akti-1/2|YX4CPQ6V6X|Akt-I 1,2|1,3-Dihydro-1-(1-((4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one|1-(1-(4-(6-Phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)benzyl)-piperidin-4-yl)-1H- |
---|---|
Specifications & Purity | ≥97% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Action Type | ALLOSTERIC MODULATOR |
Mechanism of action | Allosteric modulator of AKT serine/threonine kinase 1;Allosteric modulator of AKT serine/threonine kinase 2;Allosteric modulator of AKT serine/threonine kinase 3 |
Product Description | product description: Akti-1/2 (Akt Inhibitor VIII) is a highly selective Akt1/Akt2 inhibitor with IC50 of 58 nM/210 nM, respectively, about 36-fold selectivity for Akt1 over Akt3. Akti-1/2 induces apoptosis. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 3-[1-[[4-(6-phenyl-8H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one |
---|---|
INCHI | InChI=1S/C34H29N7O/c42-34-39-26-8-4-5-9-31(26)41(34)25-14-16-40(17-15-25)20-22-10-12-24(13-11-22)33-32(23-6-2-1-3-7-23)37-29-18-27-28(36-21-35-27)19-30(29)38-33/h1-13,18-19,21,25,38H,14-17,20H2,(H,39,42) |
InChi Key | IWCQHVUQEFDRIW-UHFFFAOYSA-N |
Canonical SMILES | C1CN(CCC1N2C3=CC=CC=C3NC2=O)CC4=CC=C(C=C4)C5=C(N=C6C=C7C(=NC=N7)C=C6N5)C8=CC=CC=C8 |
Isomeric SMILES | C1CN(CCC1N2C3=CC=CC=C3NC2=O)CC4=CC=C(C=C4)C5=C(N=C6C=C7C(=NC=N7)C=C6N5)C8=CC=CC=C8 |
PubChem CID | 135398501 |
Molecular Weight | 551.66 |
PubChem CID | 135398501 |
---|---|
ChEMBL Ligand | CHEMBL258844 |
CAS Registry No. | 612847-09-3 |
RCSB PDB Ligand | IQO |
Enter Lot Number to search for COA:
Sensitivity | Light sensitive ;Heat sensitive |
---|
1. Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE et al.. (2005) Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.. Bioorg Med Chem Lett, 15 (3): (761-4). [PMID:15664853] |
2. Nagae K et al.. (2018) Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K/Akt pathway in keratinocytes.. Diabetes Res Clin Pract, 146 (155-161). [PMID:30367901] |
3. Tutunea-Fatan E et al.. (2015) GRK2 targeted knock-down results in spontaneous hypertension, and altered vascular GPCR signaling.. J Biol Chem, 290 (8): (5141-55). [PMID:25561731] |
4. Lai Y et al.. (2016) Inhibition of mTOR sensitizes breast cancer stem cells to radiation-induced repression of self-renewal through the regulation of MnSOD and Akt.. Int J Mol Med, 37 (2): (369-77). [PMID:26707081] |
5. Xu P et al.. (2022) Hypoxia-mediated YTHDF2 overexpression promotes lung squamous cell carcinoma progression by activation of the mTOR/AKT axis.. Cancer Cell Int, 22 (13). [PMID:34996459] |
6. Naspi A et al.. (2017) IGFBP-3 inhibits Wnt signaling in metastatic melanoma cells.. Mol Carcinog, 56 (2): (681-693). [PMID:27377812] |
7. Revu S et al.. (2018) IL-23 and IL-1ß Drive Human Th17 Cell Differentiation and Metabolic Reprogramming in Absence of CD28 Costimulation.. Cell Rep, 22 (10): (2642-2653). [PMID:29514093] |
8. Sun H et al.. (2016) Let-7 miRNAs sensitize breast cancer stem cells to radiation-induced repression through inhibition of the cyclin\xa0D1/Akt1/Wnt1 signaling pathway.. Mol Med Rep, 14 (4): (3285-92). [PMID:27574028] |
9. Wang Y et al.. (2017) PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells.. Int J Oncol, 50 (2): (606-612). [PMID:28000865] |
10. Foxall E et al.. (2019) PAK4 Kinase Activity Plays a Crucial Role in the Podosome Ring of Myeloid Cells.. Cell Rep, 29 (11): (3385-3393.e6). [PMID:31825823] |
11. Cui J et al.. (2019) Proteomic Identification of Pathways Responsible for the Estradiol Therapeutic Window in AD Animal Models.. Front Cell Neurosci, 13 (437). [PMID:31680862] |
12. Mao XQ et al.. (2022) RNA-seq and ATAC-seq analyses of multilineage differentiating\xa0stress enduring\xa0cells: Comparison with dermal fibroblasts.. Cell Biol Int, 46 (9): (1480-1494). [PMID:35673985] |
13. Yang Y et al.. (2016) The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages.. Nat Commun, 7 (11385). [PMID:27150562] |
14. Tutunea-Fatan E et al.. (2015) The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis.. Mol Cancer, 14 (35). [PMID:25744065] |
15. Li N et al.. (2019) The role of Zeb1 in the pathogenesis of morbidly adherent placenta.. Mol Med Rep, 20 (3): (2812-2822). [PMID:31322233] |
16. Meng C et al.. (2020) White Spot Syndrome Virus Benefits from Endosomal Trafficking, Substantially Facilitated by a Valosin-Containing Protein, To Escape Autophagic Elimination and Propagate in the Crustacean Cherax quadricarinatus.. J Virol, 94 (24): [PMID:32967962] |